Prevention of Cervical Cancer

  • Konstantinos DoufekasEmail author
  • Yaa Achampong
  • Adeola Olaitan


Cervical cancer is the fourth most common cancer affecting women worldwide and the second commonest cancer affecting women in developing countries. In 2012 there were 530,000 new diagnoses (7.5% of all new cancer diagnoses in women) with 84% of these in resource-poor countries. In the same year, 270,000 women lost their lives to what is a preventable and treatable disease, and the overwhelming majority of these deaths were in women living in low- or middle-income countries.

Most cases of cervical cancer are attributable to infection with the human papillomavirus (HPV), with types 16 and 18 causing up to 70% of all cervical cancers and precancerous lesions. HPV is transmitted sexually. It is usually acquired soon after the onset of sexual activity and is therefore extremely common in men and women who are sexually active.

The World Health Organization strategy for the prevention of cervical cancer comprises primary, secondary, and tertiary prevention for women at different stages of their lives and in various stages of the natural history of the disease.


Cervix cancer Cervical cancer Primary prevention Secondary prevention Tertiary prevention HPV vaccine-Screening for cervical cancer Cervical malignancy 


  1. 1.
    Bray F, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132(5):1133–45.CrossRefGoogle Scholar
  2. 2.
    Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from:
  3. 3.
    Human papilloma virus (HPV) and cervical cancer WHO Fact Sheet, Updated June 2016
  4. 4.
    Goodman A. HPV testing as a screen for cervical cancer. BMJ. 2015;350:h2372.CrossRefGoogle Scholar
  5. 5.
    Kahn J. HPV vaccination for the prevention of cervical intraepithelial neoplasia. N Engl J Med. 2009;361(3):271–8.CrossRefGoogle Scholar
  6. 6.
    Quah YL, Aggarwal IM. 10 minute consultation. Discussing human papilloma virus vaccination. BMJ. 2017;357:j2730.CrossRefGoogle Scholar
  7. 7.
    Crosbie EJ, Brabin L. Cervical cancer: problem solved? Vaccinating girls against human papillomavirus. BJOG. 2010;117(2):137–42.CrossRefGoogle Scholar
  8. 8.
    Garland SM, et al. Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) Investigators. Quadrivalent vaccine against human papilloma virus to prevent anogenital diseases. N Engl J Med. 2007;357:1928–43.CrossRefGoogle Scholar
  9. 9.
    FUTURE II Study Group. Quadrivalent vaccine against human papilloma virus to prevent high-grade cervical lesions. N Engl J Med. 2007;357:1915–27.Google Scholar
  10. 10.
    Centers for Disease Control and Prevention. Human papilloma virus (HPV) vaccine safety. CDC, 2015.
  11. 11.
    Joura EA, et al. A 9-valent vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.CrossRefGoogle Scholar
  12. 12.
    De Vincenzo R, et al. Long term efficacy and safety of human papilloma virus vaccination. Int J Womens Health. 2014;357:999–1010.CrossRefGoogle Scholar
  13. 13.
    Narducci A, Einarson A, Bozzo P. Human papilloma virus vaccine and pregnancy. Can Fam Physician. 2012;58(3):268–9.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Ma B, Roden R, Wu TC. Current status of HPV vaccines. J Formos Med Assoc. 2010;109(7):481–3.CrossRefGoogle Scholar
  15. 15.
    Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries – key challenges and issues. N Engl J Med. 2007;356(19):1908–10.CrossRefGoogle Scholar
  16. 16.
    Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol. 2009;10(10):975–80.CrossRefGoogle Scholar
  17. 17.
    Yang A, et al. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23(1):75.CrossRefGoogle Scholar
  18. 18.
    Vilos GA. The history of the Papanicolaou smear and the odyssey of George and Andromache Papanicolaou. Obstet Gynecol. 1998;91(3):479–83.CrossRefGoogle Scholar
  19. 19.
    Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968. Scholar
  20. 20.
    Martin-Hirsch P. Commentary on ‘Use of a high-risk human papilloma virus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study’. BJOG. 2013;120(10):1267–8.Google Scholar
  21. 21.
    Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5(6):e132. Scholar
  22. 22.
    World Health Organisation International Agency for Research on Cancer Screening Group. Visual Inspection with Acetic Acid: Evidence to Date. 2002. Accessed 11 June 2017.
  23. 23.
    Ketelaars PJW, et al. High risk human papilloma virus detection in self-sampling compared to physician taken smear in a responder population of the Dutch cervical screening: Results of the VERA study. Prev Med. 2017;101:96–101.CrossRefGoogle Scholar
  24. 24.
    Mayrand MH, et al. Human papilloma virus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–88.CrossRefGoogle Scholar
  25. 25.
    Lazcano Ponce E, et al. Self-collection of vaginal specimens for human papilloma virus testing in cervical cancer prevention (MARCH): a community-based randomized controlled trial. Lancet. 2011;378(9806):1868–73.CrossRefGoogle Scholar
  26. 26.
    World Health Organisation, Department of Reproductive Health and Research and Department of Chronic Diseases and Health Promotion, Geneva. Comprehensive cervical cancer control: a guide to essential practice (C4-GEP) 2006. Accessed 11 June 2017.
  27. 27.
    World Health Organisation. WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention. © World Health Organization 2013 ISBN 978 9241548694.Google Scholar
  28. 28.
    Rossi G, et al. Cervical cancer screening in women vaccinated against human papilloma virus infection: recommendations from a consensus conference. Prev Med. 2017;98:21–30.CrossRefGoogle Scholar
  29. 29.
    Cervical Cancer Incidence and Screening Coverage, NCRAS.
  30. 30.
  31. 31.
    World Health Organization: Global Atlas of Palliative Care at the End of Life, 2014.
  32. 32.
    Lim AW, et al. Cytology in the diagnosis of cervical cancer in symptomatic young women: a retrospective review. Br J Gen Pract. 2016;66(653):e871–9. Epub 2016 Oct 24CrossRefGoogle Scholar
  33. 33.
    Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynaecol Obstet. 2009;105(2):103–4.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Konstantinos Doufekas
    • 1
    Email author
  • Yaa Achampong
    • 2
  • Adeola Olaitan
    • 1
  1. 1.Department of Gynaecological OncologyUniversity College London HospitalLondonUK
  2. 2.Department of Women’s HealthUniversity College London HospitalLondonUK

Personalised recommendations